New ATC 5th levels 2024
ATC code | ATC level name |
---|---|
L02BX53 | abiraterone and prednisolone |
B01AD13 | apadamtase alfa and cinaxadamtase alfa |
C02KN01 | aprocitentan |
P02BA03 | arpraziquantel |
S01AA32 | bacitracin |
C05XX01 | beperminogene perplasmid |
D03AX16 | beremagene geperpavec |
A10BK08 | bexagliflozin |
N06AX62 | bupropion and dextromethorphan |
B05XA19 1) | calcium gluconate |
L01EX27 | capivasertib |
J01DE51 | cefepime and beta-lactamase inhibitor |
J01DD58 | cefixime and beta-lactamase inhibitor |
J01DC52 | cefuroxime and beta-lactamase inhibitor |
C01CA28 | centhaquine |
A01AB53 | chlorhexidine and cetylpyridinium |
S01HA08 | chloroprocaine |
C04AX33 | clazosentan |
M04AC51 | colchicine and probenecid |
B02BX10 | concizumab |
J07BN05 | covid-19, virus-like particles |
L04AJ07 | crovalimab |
L04AJ09 | danicopan |
N05CJ03 | daridorexant |
L01BC58 | decitabine, combinations |
M09AX15 | delandistrogene moxeparvovec |
D11AH11 | delgocitinib |
S01BA16 | difluprednate |
L04AG15 | divozilimab |
N06DX05 | donanemab |
L03AA19 | eflapegrastim |
L01XX79 | eflornithine |
L02BA04 | elacestrant |
A16AB26 | eladocagene exuparvovec |
A05AX06 | elafibranor |
J05AE16 | ensitrelvir |
J07BX06 | enterovirus 71 vaccines |
L01FX27 | epcoritamab |
N07XX21 | eplontersen |
A07FA03 | escherichia coli |
B02BD16 | etranacogene dezaparvovec |
L04AE05 | etrasimod |
H05BX06 | evocalcet |
B06AX05 | exagamglogene autotemcel |
L01EK04 | fruquintinib |
M09AX14 | givinostat |
L01FX28 | glofitamab |
N02AJ23 | hydrocodone and ibuprofen |
N02AJ22 | hydrocodone and paracetamol |
L01XX80 | imetelstat |
A10AE07 | insulin icodec |
L04AJ08 | iptacopan |
A02BX16 | irsogladine |
D11AH10 | lebrikizumab |
N06DX04 | lecanemab |
L03AX22 | leniolisib |
A16AX23 | leriglitazone |
L04AC25 | levilimab |
L01XL11 | lifileucel |
B01AC28 | limaprost |
L01XL08 | lisocabtagene maraleucel |
V04CX11 | lithium chloride |
S01CA12 | loteprednol and antiinfectives |
N02BA67 | magnesium salicylate, combinations excl. psycholeptics |
A10BD28 | metformin and teneligliptin |
L04AC24 | mirikizumab |
L01FX26 | mirvetuximab soravtansine |
L01EJ04 | momelotinib |
L01FX25 | mosunetuzumab |
L01XL10 | nadofaragene firadenovec |
M01AE57 | naproxen and diphenhydramine |
L01XX78 | navitoclax |
D11AH12 | nemolizumab |
L01XK52 | niraparib and abiraterone |
C01CX10 | omecamtiv mecarbil |
A02BC51 | omeprazole, combinations |
L01EL04 | orelabrutinib |
A16AB27 | pabinafusp alfa |
H05AA05 | palopegteriparatide |
S01XA31 | pegcetacoplan |
C10AB12 | pemafibrate |
N02AD51 | pentazocine and naloxone |
C09BX06 | perindopril, bisoprolol, amlodipine and indapamide |
C05AX06 | phenylephrine |
L01EL05 | pirtobrutinib |
S01AX24 | polihexanide |
V03AB54 | pralidoxime and atropine |
L01FY03 | prolgolimab and nurulimab |
J05AP13 | ravidasvir |
J07BX05 | respiratory syncytial virus vaccines |
L04AF08 | ritlecitinib |
B01AF51 | rivaroxaban and acetylsalicylic acid |
D05AX06 | roflumilast |
C10BX21 | rosuvastatin and perindopril |
C10BX20 | rosuvastatin and telmisartan |
L04AG16 | rozanolixizumab |
R03AK15 | salbutamol and budesonide |
L03AB17 | sampeginterferon beta-1a |
L01FF12 | serplulimab |
A10BD29 | sitagliptin and dapagliflozin |
L01EX26 | sitravatinib |
N07XX19 | sodium phenylbutyrate and ursodoxicoltaurine |
G04BX17 | sodium salicylate and methenamine |
B05XA20 2) | sodium selenite |
J05AR28 | stavudine and lamivudine |
L01FF11 | sugemalimab |
N02CC51 | sumatriptan and naproxen |
L01XL09 | tabelecleucel |
L01FX29 | talquetamab |
D05AX07 | tapinarof |
V09IA10 | technetium (99mTc) trofolastat chloride |
L01FX24 | teclistamab |
A10XX01 | teplizumab |
N07XX22 | tofersen |
L01FF13 | toripalimab |
N07XX23 | troriluzole |
A05AA05 | ursodoxicoltaurine |
B02BD15 | valoctocogene roxaparvovec |
H02AB18 | vamorolone |
G04BD15 | vibegron |
A02BD17 | vonoprazan and amoxicillin |
L04AJ06 | zilucoplan |
C09BX07 | zofenopril and nebivolol |
1) Parenteral formulations should be classified here. Oral preparations should be classified in A12AA03.
2) Parenteral formulations should be classified here. Oral preparations should be classified in A12CE02.
2) Parenteral formulations should be classified here. Oral preparations should be classified in A12CE02.
Last updated: 2023-12-15